ClinicalTrials.gg
Not yet recruitingNCT07947732Updated Nov 19, 2026

Study of Twice Yearly Lenacapavir, Teropavimab, and Zinlirvimab in the Pediatric Population With HIV-1

A Phase 2/3 interventional study of Lenacapavir Tablet and Lenacapavir Injection in HIV-1-infection, sponsored by Gilead Sciences. Not yet recruiting at 2 sites in United States. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
12 Years to 18 Years
Sex
All
01

Study summary

The goal of this clinical study is to learn more about the study drugs lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) to assess how it is absorbed, modified, distributed and eliminated from the body of young people (the pharmacokinetics (PK) parameters of the drugs). It will also check the safety, and tolerability of LEN in combination with TAB, and ZAB in participants living with human immunodeficiency virus type 1 (HIV-1).

The primary objectives of this study are to evaluate the PK parameters, safety, and tolerability of LEN, TAB, and ZAB.

02

Conditions studied

  • HIV-1-infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 693 studies on the registry; 27 are open to participants now.

Of its 262 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Individuals must be aged ≥ 12 to \< 18 years at Screening Visit 1 (SV1) and enrollment (Day 1).
  • Weight ≥ 35 kg at Day 1.
  • On a stable oral antiretroviral (ARV) regimen for at least 6 months prior to SV1.
  • At least 1 documented -1 RNA level measured between 6 months and 12 months (+ 2 months) prior to SV1. This and any other HIV-1 RNA measurements documented in this period must be \< 50 copies/mL (undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).
  • A plasma HIV-1 RNA test \< 50 copies/mL (undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL) within the last 6 months prior to SV1.
  • Plasma HIV-1 RNA \< 50 copies/mL at Screening Visit 2 (SV2).
  • HIV-1 susceptibility results to TAB and ZAB meeting specific protocol criteria.
  • ≥ 200 cells/mm\^3 at SV2.
  • CD4 individuals ≥ 20% at SV2.

Key Exclusion Criteria:

  • History of an opportunistic infection or illness indicative of Stage 3 HIV disease.
  • ≤ 1 year.
  • Evidence of active pulmonary or extrapulmonary tuberculosis infection within 3 months prior to Day 1.
  • Acute hepatitis of any cause \< 30 days before Day 1 visit.
  • History of, or current clinical decompensated liver cirrhosis or severe hepatic impairment.
  • Prior use of, or exposure to LEN, TAB, ZAB, cabotegravir (CAB) (oral or injectable), rilpivirine (RPV) (injectable), or any long-acting (LA) parenteral ARVs (ie, broadly neutralizing antibodies (bNAbs)).
  • Any exclusionary laboratory values at SV2
  • Positive virus (HCV) antibody with detectable HCV RNA.
  • Chronic virus (HBV) infection

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Lenacapavir (LEN) + Teropavimab (TAB) + Zinlirvimab (ZAB)

    Participants will receive oral LEN 600 mg, subcutaneous (SC) LEN 927 mg, and intravenously (IV) infusions of TAB and ZAB on Day 1. Participants will self-administer oral LEN 600 mg on Day 2. At Week 26: Participants will then receive a second dose of LEN 927 mg SC injection along with TAB and ZAB IV infusion. At Week 52 participants will be given the option to enter the extension phase to continue receiving LEN 600 mg orally and TAB and ZAB IV infusions until participants either discontinue the study treatment or discontinue the extension phase (EXT), or the study is discontinued at the sponsor's sole discretion, whichever occurs first.

    Drug: Lenacapavir Tablet · Drug: Lenacapavir Injection · Drug: Teropavimab · Drug: Zinlirvimab

Interventions

  • DrugLenacapavir Tablet

    Administered orally

    Also known as: LEN

  • DrugLenacapavir Injection

    Administered SC

    Also known as: LEN, SUNLENCA®

  • DrugTeropavimab

    Administered IV

    Also known as: TAB, GS-5423

  • DrugZinlirvimab

    Administered IV

    Also known as: ZAB, GS-2872

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) parameters: Ctrough for LEN During the First Dosing Cycle (Day 1 to Week 26)

    Ctrough is defined as the concentration at the end of the dosing interval. Cycle length is 26 weeks.

    Time frame: Day 1 to Week 26

  2. Pharmacokinetics (PK) parameters: Ctrough for TAB During the First Dosing Cycle (Day 1 to Week 26)

    Ctrough is defined as the concentration at the end of the dosing interval. Cycle length is 26 weeks.

    Time frame: Day 1 to Week 26

  3. Pharmacokinetics (PK) parameters: Ctrough for ZAB During the First Dosing Cycle (Day 1 to Week 26)

    Ctrough is defined as the concentration at the end of the dosing interval. Cycle length is 26 weeks.

    Time frame: Day 1 to Week 26

  4. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) Through Week 26

    Time frame: First dose date up to Week 26

  5. Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Through Week 26

    Time frame: First dose date up to Week 26

Secondary outcomes

  1. PK Parameter: Cmax for LEN During the First Dosing Cycle (Day 1 to Week 26)

    Cmax is defined as the maximum observed concentration of drug. Cycle length is 26 weeks.

    Time frame: Day 1 to Week 26

  2. PK Parameter: Cmax for TAB During the First Dosing Cycle (Day 1 to Week 26)

    Cmax is defined as the maximum observed concentration of drug. Cycle length is 26 weeks.

    Time frame: Day 1 to Week 26

  3. PK Parameter: Cmax for ZAB During the First Dosing Cycle (Day 1 to Week 26)

    Cmax is defined as the maximum observed concentration of drug. Cycle length is 26 weeks.

    Time frame: Day 1 to Week 26

  4. PK Parameter: Tmax for LEN During the First Dosing Cycle (Day 1 to Week 26)

    Tmax is defined as the time (observed time point) of Cmax. Cycle length is 26 weeks.

    Time frame: Day 1 to Week 26

  5. PK Parameter: Tmax for TAB During the First Dosing Cycle (Day 1 to Week 26)

    Tmax is defined as the time (observed time point) of Cmax. Cycle length is 26 weeks.

    Time frame: Day 1 to Week 26

  6. PK Parameter: Tmax for ZAB During the First Dosing Cycle (Day 1 to Week 26)

    Tmax is defined as the time (observed time point) of Cmax. Cycle length is 26 weeks.

    Time frame: Day 1 to Week 26

  7. PK Parameter: t1/2 for LEN during the first dosing cycle (Day 1 to Week 26)

    t1/2 is defined as the terminal elimination half-life. Cycle length is 26 weeks.

    Time frame: Day 1 to Week 26

  8. PK Parameter: t1/2 for TAB during the first dosing cycle (Day 1 to Week 26)

    t1/2 is defined as the terminal elimination half-life. Cycle length is 26 weeks.

    Time frame: Day 1 to Week 26

  9. PK Parameter: t1/2 for ZAB during the first dosing cycle (Day 1 to Week 26)

    t1/2 is defined as the terminal elimination half-life. Cycle length is 26 weeks.

    Time frame: Day 1 to Week 26

  10. PK Parameter: AUCtau for LEN During the First Dosing Cycle (Day 1 to Week 26)

    AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Cycle length is 26 weeks.

    Time frame: Day 1 to Week 26

  11. PK Parameter: AUCtau for TAB During the First Dosing Cycle (Day 1 to Week 26)

    AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Cycle length is 26 weeks.

    Time frame: Day 1 to Week 26

  12. PK Parameter: AUCtau for ZAB During the First Dosing Cycle (Day 1 to Week 26)

    AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Cycle length is 26 weeks.

    Time frame: Day 1 to Week 26

  13. PK Parameter: Ctrough for LEN During the Second Dosing Cycle (Week 26 to Week 52)

    Ctrough is defined as the observed drug concentration at the end of the dosing interval at steady state. Cycle length is 26 weeks to 52 weeks.

    Time frame: Week 26 to Week 52

  14. PK Parameter: Ctrough for TAB During the Second Dosing Cycle (Week 26 to Week 52)

    Ctrough is defined as the observed drug concentration at the end of the dosing interval at steady state. Cycle length is 26 weeks to 52 weeks.

    Time frame: Week 26 to Week 52

  15. PK Parameter: Ctrough for ZAB During the Second Dosing Cycle (Week 26 to Week 52)

    Ctrough is defined as the observed drug concentration at the end of the dosing interval at steady state. Cycle length is 26 weeks to 52 weeks.

    Time frame: Week 26 to Week 52

  16. Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 52

    Time frame: First dose date up to Week 52

  17. Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Through Week 52

    Time frame: First dose date up to Week 52

  18. Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 26 Based on the United States (US) FDA-Defined Snapshot Algorithm

    Time frame: Week 26

  19. Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 52 Based on the US FDA-Defined Snapshot Algorithm

    Time frame: Week 52

  20. Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Weeks 26 Based on the US FDA-Defined Snapshot Algorithm

    Time frame: Week 26

  21. Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL at Week 52 Based on the US FDA-Defined Snapshot Algorithm

    Time frame: Week 52

  22. Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 26

    Time frame: Baseline, Week 26

  23. Change From Baseline in CD4 Cell Percentage at Week 26

    Time frame: Baseline, Week 26

  24. Change From Baseline in CD4 Cell Count at Week 52

    Time frame: Baseline, Week 52

  25. Change From Baseline in CD4 Cell Percentage at Week 52

    Time frame: Baseline, Week 52

  26. Percentage of Participants With of Anti-Drug Antibodies (ADA) Against TAB Through Week 26

    Time frame: First dose date up to Week 26

  27. Percentage of Participants With Neutralizing Antibodies (NAbs) Against TAB Through Week 26

    Time frame: First dose date up to Week 26

  28. Percentage of Participants With ADA Against ZAB through Week 26

    Time frame: First dose date up to Week 26

  29. Percentage of Participants With NAbs Against ZAB through Week 26

    Time frame: First dose date up to Week 26

  30. Percentage of Participants With ADA Against TAB through Week 52

    Time frame: First dose date up to Week 52

  31. Percentage of Participants With NAbs Against TAB through Week 52

    Time frame: First dose date up to Week 52

  32. Percentage of Participants With ADA Against ZAB through Week 52

    Time frame: First dose date up to Week 52

  33. Percentage of Participants With NAbs Against ZAB through Week 52

    Time frame: First dose date up to Week 52

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 2028
CompletionEst.
May 2032
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947732
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2028 (estimated)
Completion
May 2032 (estimated)
Last update
Nov 19, 2026

Study contacts

Gilead Clinical Study Information Center
Contact
GileadClinicalTrials@gilead.com
1-833-445-3230 (GILEAD-0)
Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion